Corporate News Fuels Stock Surges: Julong Holding Limited (NASDAQ: JLHL) and Other Top Gainers

Exceptional Small-Cap Rally: Julong Holding Limited (NASDAQ: JLHL) recorded the largest gain, rising more than 300% amid extremely heavy trading volume, although no clear new company-specific catalyst was identified.

Clinical Data Supports Biotech Gain: Forte Biosciences, Inc. (NASDAQ: FBRX) surged after reporting positive Phase 1b clinical data for FB102 in patients with vitiligo.

Financing and Speculative Activity: Virax Biolabs Group Limited (NASDAQ: VRAX), First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX), and Sadot Group Inc. (NASDAQ: SDOT) also posted substantial gains, although the reasons behind some of the moves were less clear.

Several small-cap stocks recorded sharp price increases on July 9, 2026. The day’s leading gainers included Julong Holding Limited (NASDAQ: JLHL), Virax Biolabs Group Limited (NASDAQ: VRAX), Forte Biosciences, Inc.(NASDAQ: FBRX), First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX), and Sadot Group Inc. (NASDAQ: SDOT). While some gains coincided with major company announcements, other moves occurred without a clearly identified same-day catalyst.

Shares of Julong Holding Limited surged 317.97%, gaining $9.73 to close at $12.79. Trading volume exceeded 75 million shares, substantially above the stock’s typical activity. The company provides intelligent integrated systems and services for infrastructure projects in China.

Although Julong Holding Limited announced changes to its board and committee structure in June, those changes occurred several weeks before the July 9 rally. No clear new corporate announcement was identified as the direct cause of the stock’s sharp increase. The move may therefore have reflected speculative trading, unusually strong demand, or elevated volatility in the relatively small company’s shares.

Shares of Virax Biolabs Group Limited rose approximately 102% to close at $6.36. During the trading session, the biotechnology company announced an agreement involving the immediate exercise of preferred investment options covering up to 548,000 ordinary shares.

The exercise price was reduced from $10.00 to $6.00 per share, and the transaction was expected to generate approximately $3.3 million in gross proceeds before fees and expenses. However, the stock had already risen substantially before the financing announcement was released and traded as high as approximately $13 during the session. The financing should therefore not be viewed as the confirmed cause of the full-day gain.

Forte Biosciences, Inc. shares increased 78.33% to $36.70 after the company reported positive Phase 1b clinical results for FB102 in patients with vitiligo. The study showed a statistically significant improvement in facial vitiligo measurements at Week 24 following a 12-week treatment period.

The results provide encouraging early clinical evidence for FB102. However, Phase 1b findings remain an early stage of clinical development and do not indicate that regulatory approval or commercialization is imminent. Additional studies would generally be required to further evaluate the treatment’s effectiveness and safety.

Shares of First Tracks Biotherapeutics, Inc. increased 55.99% to close at $32.40. The clinical-stage biotechnology company is developing antibody therapies for autoimmune and inflammatory diseases.

Although the company is scheduled to participate in the Leerink Partners Therapeutics Forum on July 14, the conference participation was announced in May and does not represent a new same-day development. No clear July 9 company announcement was identified as the primary cause of the share-price increase.

Sadot Group Inc. rose 32.30% to close at $26.71. The company operates in the global agricultural commodity supply chain and recently expanded its operations through the acquisition of Anira Consulting FZC.

However, the Anira transaction was completed on June 2, more than a month before the July 9 rally. Although the acquisition may remain part of the company’s broader investment narrative, no clear new announcement connected the transaction directly to the latest share-price increase.

Overall, the day’s largest gains reflected a combination of clinical developments, financing activity, elevated trading volume, and speculative interest in small-cap stocks. Positive Phase 1b results provided a clear catalyst for Forte Biosciences, Inc., while the sharp increases in Julong Holding Limited, First Tracks Biotherapeutics, Inc., and Sadot Group Inc. occurred without clearly identified same-day corporate developments. The increase in Virax Biolabs Group Limited coincided with a financing announcement, although the stock had already risen sharply before the news was released.